Cannabinoid Receptor Binding Agents, Compositions and Methods

Abstract

A composition comprising a cannabinoid receptor binding agent contained in a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.

What is claimed is: 
     
         1 . A composition and drug delivery vehicle, comprising:
 a. a cannabinoid receptor binding agent present at about 1% to about 55% by weight of the composition;   b. a polymeric nanoparticle containing the cannabinoid receptor binding agent wherein the polymeric nanoparticle at its largest dimension is smaller than 400 nanometers and greater than 0 nanometers, wherein the polymeric nanoparticle comprises a biodegradable polymer, wherein the polymeric nanoparticle is present at 75% or less and greater than 1% by weight of the composition, and wherein the biodegradable polymer is selected from the group consisting of polylactides, polyglycolides, poly(lactide-co-glycolide)s, polylactic acids, polyglycolic acids, poly(lactic acid-co-glycolic acid)s, copolymers of polylactides and poly(lactide-co-glycolide)s, poly(amino acids), polyacrylates, polyketals, collagen, chitin, chitosan, dextran, alginate, gelatin, albumin, ovalbumin, elastin, laminin, fibronectin, polymerized starches, chondroitin sulfate, polysucrose, hyaluronic acid, and heparin; and   c. a vesicle for carrying the cannabinoid receptor binding agent and the polymeric nanoparticle.   
     
     
         2 . The composition and drug delivery vehicle of  claim 1 , wherein the vesicle comprises a phospholipid selected from the group consisting of a liposome, an ethosome, a noisome, and a transferosome. 
     
     
         3 . The composition and drug delivery vehicle of  claim 2 , wherein the vesicle is a multilamellar liposomal vesicle have a plurality of layers, wherein each layer has a different property. 
     
     
         4 . The composition and drug delivery vehicle of  claim 1 , wherein the particle comprises a nanocrystalline cellulose present at about 5% to about 40% by weight of the composition. 
     
     
         5 . A drug delivery device containing a composition, comprising:
 a. cannabinoid receptor binding agents present at about 1% to about 55% by weight of the composition;   b. polymeric nanoparticles containing the cannabinoid receptor binding agents, wherein the polymeric nanoparticles are present at about 75% or less and greater than 1% by weight of the composition, wherein the polymeric nanoparticles at their largest dimensions are smaller than 400 nanometers and greater than zero nanometers, and wherein the polymeric nanoparticles comprise a biodegradable polymer selected from the group consisting of polylactides, polyglycolides, poly(lactide-co-glycolide)s, polylactic acids, polyglycolic acids, poly(lactic acid-co-glycolic acid)s, copolymers of polylactides, and poly(lactide-co-glycolide)s, poly(amino acids), polyacrylates, polyketals, collagen, chitin, chitosan, dextran, alginate, gelatin, albumin, ovalbumin, elastin, laminin, fibronectin, polymerized starches, chondroitin sulfate, polysucrose, hyaluronic acid, and heparin; and   c. a substrate for delivering the cannabinoid receptor binding agents and the polymeric nanoparticles, wherein the substrate is selected from the group consisting of a patch and a non-solid composition that is solidified when exposed to a suitable agent selected from the group consisting of light, heat, and a chemical activating agent.   
     
     
         6 . The drug delivery device of  claim 5 , wherein the particles are nanocrystalline cellulose present at about 5% to about 40% by weight of the composition. 
     
     
         7 . The drug delivery device of  claim 5 , further comprising a functional moiety attached to the polymeric nanoparticle. 
     
     
         8 . The drug delivery device of  claim 7 , wherein the functional moiety is a crosslinking moiety. 
     
     
         9 . The drug delivery device of  claim 8 , wherein the crosslinking moiety comprises an ester and a sulfhydryl reactive group. 
     
     
         10 . The drug delivery device of  claim 5 , wherein the polymeric nanoparticle is chemically attached to a moiety, wherein the moiety comprises:
 a. a sulfonate attached to the polymeric nanoparticle,   b. a spacer attached to the sulfonate, and   c. a functional group attached to the sulfonate via the spacer.   
     
     
         11 . The drug delivery device of  claim 5 , wherein the polymeric nanoparticle further comprises a coating selected from the group consisting of albumin and silicone. 
     
     
         12 . A composition, comprising:
 a. cannabidiol present at about 1% to about 55% by weight of the composition, wherein the cannabidiol is selected from the group consisting of cannabidiol-C5, cannabidiol momomethyl ether, cannabidiol-C4, cannabidivarin, cannabidiorcol, cannabidiolic acid, and cannabidivarinic acid; and   b. a polymeric nanoparticle containing the cannabidiol wherein the polymeric nanoparticle at its largest dimension is smaller than 400 nanometers and greater than 0 nanometers, wherein the polymeric nanoparticle comprises a biodegradable polymer, wherein the polymeric nanoparticle is present at 75% or less and greater than 1% by weight of the composition, and wherein the biodegradable polymer is selected from the group consisting of polylactides, polyglycolides, poly(lactide-co-glycolide)s, polylactic acids, polyglycolic acids, poly(lactic acid-co-glycolic acid)s, copolymers of polylactides and poly(lactide-co-glycolide)s, poly(amino acids), polyacrylates, polyketals, collagen, chitin, chitosan, dextran, alginate, gelatin, albumin, ovalbumin, elastin, laminin, fibronectin, polymerized starches, chondroitin sulfate, polysucrose, hyaluronic acid, and heparin.   
     
     
         13 . The composition of  claim 12 , further comprising a functional moiety attached to the polymeric nanoparticle. 
     
     
         14 . The composition of  claim 13 , wherein the functional moiety is a crosslinking moiety. 
     
     
         15 . The composition of  claim 14 , wherein the crosslinking moiety comprises an ester and a sulfhydryl reactive group. 
     
     
         16 . The composition of  claim 13 , wherein the functional moiety comprises:
 a. a sulfonate attached to the polymeric nanoparticle,   b. a spacer attached to the sulfonate, and   c. a functional group attached to the sulfonate via the spacer.   
     
     
         17 . The composition of  claim 12 , wherein the polymeric nanoparticle further comprises a coating selected from the group consisting of albumin and silicone. 
     
     
         18 . The composition of  claim 12 , further comprising a vesicle for carrying the cannabidiol and the polymeric nanoparticle. 
     
     
         19 . The composition of  claim 18 , wherein the vesicle comprises a phospholipid selected from the group consisting of a liposome, an ethosome, a noisome, and a transferosome. 
     
     
         20 . The composition of  claim 19 , wherein the vesicle is a multilamellar liposomal vesicle have a plurality of layers, wherein each layer has a different property.